NYSE:AVNSAvanos Medical Stock Price, Forecast & News

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVNS stock has decreased by 1.2% and is now trading at $28.67. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical.

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Avanos Medical.

Avanos Medical Inc (NYSE:AVNS) released its quarterly earnings data on Wednesday, May, 6th. The company reported $0.16 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.16. The business earned $180.40 million during the quarter, compared to the consensus estimate of $175.15 million. Avanos Medical had a positive return on equity of 4.09% and a negative net margin of 3.07%. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.15 earnings per share. View Avanos Medical's earnings history.

7 brokerages have issued 1 year price targets for Avanos Medical's stock. Their forecasts range from $30.00 to $48.00. On average, they expect Avanos Medical's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View analysts' price targets for Avanos Medical.

Media stories about AVNS stock have trended negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avanos Medical earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Avanos Medical.

Avanos Medical saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 2,370,000 shares, a drop of 13.8% from the May 31st total of 2,750,000 shares. Based on an average trading volume of 430,000 shares, the short-interest ratio is presently 5.5 days. Currently, 5.1% of the shares of the stock are short sold. View Avanos Medical's Current Options Chain.

Some companies that are related to Avanos Medical include Wound Management Technologies (WNDM), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), Lakeland Industries (LAKE), RTI Surgical (RTIX), Sientra (SIEN), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Histogenics (HSGX), Precision Therapeutics (POAI) and Rewalk Robotics (RWLK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), AT&T (T), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Procter & Gamble (PG), Verizon Communications (VZ), Home Depot (HD), Johnson & Johnson (JNJ) and Altria Group (MO).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Confluence Investment Management LLC (1.16%) and Diversified Trust Co (0.03%). Company insiders that own Avanos Medical stock include Gary Blackford, John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View institutional ownership trends for Avanos Medical.

AVNS stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC. View insider buying and selling activity for Avanos Medical.

AVNS stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, John W Wesley, Joseph Fralin Woody, and Steven E Voskuil. View insider buying and selling activity for Avanos Medical.

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVNS stock can currently be purchased for approximately $28.67.

Avanos Medical has a market capitalization of $1.37 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.

The official website for Avanos Medical is avanos.com.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]